Refine
Year of publication
Document Type
- Preprint (779)
- Article (772)
- Conference Proceeding (7)
- Working Paper (2)
- Book (1)
- Doctoral Thesis (1)
- Other (1)
- Part of Periodical (1)
Has Fulltext
- yes (1564)
Is part of the Bibliography
- no (1564)
Keywords
- Heavy Ion Experiments (21)
- Hadron-Hadron scattering (experiments) (12)
- Hadron-Hadron Scattering (11)
- LHC (9)
- Heavy-ion collision (6)
- Heavy-ion collisions (5)
- immunotherapy (5)
- ALICE experiment (4)
- CIK cells (4)
- Collective Flow (4)
- HIV (4)
- Jets (4)
- Quark-Gluon Plasma (4)
- ALICE (3)
- Breast cancer (3)
- COVID-19 (3)
- Diffraction (3)
- Elastic scattering (3)
- Heavy Ions (3)
- Heavy Quark Production (3)
- Jets and Jet Substructure (3)
- Machine learning (3)
- Predictive markers (3)
- Prostate cancer (3)
- allogeneic stem cell transplantation (3)
- children (3)
- cytokine-induced killer cells (3)
- global change (3)
- pp collisions (3)
- rhabdomyosarcoma (3)
- Acuris (2)
- Beam Energy Scan (2)
- Beauty production (2)
- Bipolar disorder (2)
- Charm physics (2)
- Chiral Magnetic Effect (2)
- Clinical Trials and Observations (2)
- Collectivity (2)
- Consensus (2)
- Correlation (2)
- Diagnostic markers (2)
- Diagnostik (2)
- Elliptic flow (2)
- EphB4 (2)
- Experimental nuclear physics (2)
- Experimental particle physics (2)
- Früherkennung (2)
- Genetics (2)
- Lepton-Nucleon Scattering (experiments) (2)
- Mammakarzinom (2)
- NK cells (2)
- Nachsorge (2)
- Oncology (2)
- Particle Correlations and Fluctuations (2)
- Particle and resonance production (2)
- Particle correlations and fluctuations (2)
- Pb–Pb collisions (2)
- Polarization (2)
- Psychiatric disorders (2)
- Pulmonary embolism (2)
- QCD (2)
- Quarkonium (2)
- RHIC (2)
- Radiotherapy (2)
- Relativistic heavy-ion collisions (2)
- Richtlinie (2)
- STAR (2)
- Shear viscosity (2)
- Single electrons (2)
- Statistical analysis (2)
- Surgery (2)
- Taxonomy (2)
- biodiversity protection (2)
- biomarker (2)
- bone metastasis (2)
- breast cancer (2)
- cell therapy (2)
- chimeric antigen receptor (2)
- cirrhosis (2)
- conservation funding (2)
- conservation planning (2)
- decision making (2)
- diagnosis (2)
- ephrinB2 (2)
- flow cytometry (2)
- follow‑up (2)
- glioblastoma (2)
- glioma (2)
- guideline (2)
- hematopoietic stem cell transplantation (2)
- immune reconstitution (2)
- leukemia (2)
- lymphoma (2)
- meningioma (2)
- molecular machines (2)
- post-2020 biodiversity targets (2)
- reference values (2)
- screening (2)
- strategic site selection (2)
- 140Ce (1)
- 16S (1)
- 900 GeV (1)
- AB-serum (1)
- ABC proteins, ribosome recycling (1)
- ABC transporters (1)
- AKI (1)
- ALICE detector (1)
- AML (1)
- APRI (1)
- ARDS (1)
- ATPases (1)
- Actin (1)
- Active middle ear implants (1)
- Activities of daily living (1)
- Acute inflammation (1)
- Advanced biliary tract cancer (1)
- Allogeneic hematopoietic stem (1)
- Allogeneic stem cell transplantation (1)
- Anandamide (1)
- Angiogenesis (1)
- Anti-nuclei (1)
- Antibiotics (1)
- Antibody isotypes (1)
- Antigen-presenting cells (1)
- Antiretroviral therapy (1)
- Antiretrovirals (1)
- Antirheumatic agents (1)
- Apes (1)
- Artesunate (1)
- Artificial Intelligence (1)
- Artificial intelligence (1)
- Ataxia-telangiectasia (1)
- Auditory system (1)
- Autologous stem cell transplantation (1)
- Awareness campaign (1)
- B cell subpopulations (1)
- B-slope (1)
- BRCA1 (1)
- BRCA2 (1)
- BTC (1)
- BV6 (1)
- Backpropagating action potential (1)
- Bacterial leakage (1)
- Bacterial pathogens (1)
- Beam energy scan (1)
- Bidirectional genes (1)
- Big Data (1)
- Biodiversity Data (1)
- Biodiversity conservation (1)
- Biogeography (1)
- Bioinformatics (1)
- Biological (1)
- Biomonitoring (1)
- Blood (1)
- Bone conduction devices (1)
- Bone marrow (1)
- Bone metastases (1)
- Bone strength assessment (1)
- Boosted Jets (1)
- Borrelia burgdorferi (1)
- Botanical Collections (1)
- Buchbesprechung (1)
- Burns (1)
- Business strategy in drug development (1)
- C1-INH (C1 inhibitor, C1-esterase inhibitor) (1)
- CAD/ CAM crown (1)
- CAD/CAM crown (1)
- CAR (1)
- CCL2 (1)
- CD16 (1)
- CD3/19 depletion (1)
- CD3/CD19 depletion (1)
- CD34 selection (1)
- CD56 (1)
- CDI (1)
- COI (1)
- COMT (1)
- CTLA-4 (1)
- CVID (1)
- Calcium (1)
- Calcium gluconate (1)
- Cancer (1)
- Cancer check up (1)
- Cancer detection and diagnosis (1)
- Canonical suppression (1)
- Cardiac surgery (1)
- Cardiomyopathy (1)
- Cell membranes (1)
- Cement gap (1)
- Centrality Class (1)
- Centrality Selection (1)
- Charge fluctuations (1)
- Charged-particle multiplicity (1)
- Charm quark spatial diffusion coefficient (1)
- Charmonia (1)
- Chemoradiotherapy (1)
- Cherenkov counter: lead-glass (1)
- Child (1)
- Children (1)
- Chimerism (1)
- Chiral magnetic effect (1)
- Chronic hepatitis C (1)
- Circadian (1)
- Cirrhosis (1)
- Cleanliness level (1)
- Clinical study (1)
- Clinical variation (1)
- Closure (1)
- Coalescence (1)
- Cognitive impairment (1)
- Cold nuclear matter effects (1)
- Collective Flow, (1)
- Colon capsule endoscopy (1)
- Community dynamics (1)
- Comparative effectiveness research (1)
- Comparison with QCD (1)
- Compartmental modeling (1)
- Complement system (1)
- Complementation rate (1)
- Complex I (1)
- Computer simulation (1)
- Conometric connection (1)
- Consensus statement (1)
- Conservation (1)
- Coronary heart disease (1)
- Critical care (1)
- Critical point (1)
- Culturomics (1)
- DST (1)
- Data sharing (1)
- Dendritic spines (1)
- Depression (1)
- Dermatomyositis (1)
- Deuteron production (1)
- Di-hadron correlations (1)
- Diagnosis (1)
- Diagnostic differentiation (1)
- Digital humanities (1)
- Digital subtraction angiography (1)
- Digitization (1)
- Dilated cardiomyopathy (1)
- Dinarides (1)
- Direct Acting Antivirals (DAA) (1)
- Direct oral anticoagulation (1)
- Docetaxel (1)
- Drug susceptibility testing (1)
- Drug therapy (1)
- EGFR (1)
- EGFR inhibitor (1)
- ERBB2 (1)
- ERBB2 (HER2/neu) (1)
- Ecology (1)
- Ecophysiology (1)
- Elderly (1)
- Electromagnetic transitions (1)
- Electron-pion identification (1)
- Electrotonic analysis (1)
- Electroweak interaction (1)
- Employment (1)
- Ena/VASP proteins (1)
- Enzyme-linked immunoassays (1)
- Ephrin-B2–EphB4 (1)
- Epigenetics (1)
- Epstein-Barr virus (1)
- Etanercept (1)
- Europe (1)
- European Society for Immunodeficiencies (ESID) (1)
- Ewing sarcoma (1)
- Exosomes (1)
- Extended donor criteria (1)
- FIB-4 (1)
- Falciparum (1)
- Fc receptor (1)
- Femoral neck (1)
- Femtoscopy (1)
- Fertility counseling (1)
- Fibre/foam sandwich radiator (1)
- Fibrotest (1)
- First-line combination antiretroviral therapy (1)
- Fistula (1)
- Flow (1)
- Flow cytometry (1)
- Forschung (1)
- Forward physics (1)
- Fracture risk (1)
- Frailty (1)
- GFAP (1)
- Gadobutrol (1)
- Gadopentate dimeglumine (1)
- Gene expression (1)
- General practitioners (1)
- Genetic causes of cancer (1)
- Genetic testing (1)
- Genetics research (1)
- German PID-NET registry (1)
- Glioblastoma (1)
- Glioblastoma survival (1)
- Granule cell (1)
- Groomed jet radius (1)
- Guanine nucleotide exchange factors (1)
- Guanosine triphosphatase (1)
- Guidelines (1)
- HADES (1)
- HBT (1)
- HBV (1)
- HCV (1)
- HDAC4 (1)
- HER2-positive (1)
- HER2/neu (1)
- HIPPO signalling (1)
- HIV-1 (1)
- HNO (1)
- Hadron production (1)
- Hadron-Hadron Scattering Heavy (1)
- Hadron-hadron interactions (1)
- Hadronization (1)
- Hals-Nasen-Ohren-Heilkunde (1)
- Hand-foot syndrome (1)
- Hard Scattering (1)
- Head and neck cancer (1)
- Health policy (1)
- Heart (1)
- Heart transplantation (1)
- Heavy Ion Experiment (1)
- Heavy flavor production (1)
- Heavy flavour production (1)
- Heavy ion collisions (1)
- Heavy ions (1)
- Heavy-Ion Collision (1)
- Heavy-flavor decay electron (1)
- Heavy-flavour decay muons (1)
- Heavy-flavour production (1)
- Heavy-ion (1)
- Hepatitis C (1)
- Hepatitis C virus (1)
- Hepatotoxicity (1)
- Herbaria (1)
- Hereditary angioedema (1)
- Hereditary breast and ovarian cancer (1)
- Hif-1 alpha (1)
- Hif1α (1)
- High-dose chemotherapy (1)
- Higher moments (1)
- Histology (1)
- Homeostatic plasticity (1)
- Horses (1)
- Human behaviour (1)
- Human genetics (1)
- Hydrofluoric acid (1)
- Hypertension (1)
- IL-10 (1)
- IL-15 (1)
- IL-21 (1)
- IL-6 (1)
- IgG substitution therapy (1)
- Immunoassays (1)
- Immunogenetics (1)
- Immunology (1)
- Immunosuppressive therapy (1)
- Immunotherapy (1)
- Inclusive spectra (1)
- Incomplete colonoscopy (1)
- Indication for fertility preservation (1)
- Individual based modeling (1)
- Induction chemotherapy (1)
- Inflammation (1)
- Influenza (1)
- Intensity interferometry (1)
- Interference fragmentation function (1)
- Intra-abdominal infection (1)
- Invariant Mass Distribution (1)
- Inverse kinematics (1)
- Ionisation energy loss (1)
- Isoscalar giant resonances (1)
- J/ψ suppression (1)
- Jet Physics (1)
- Jet Substructure (1)
- Jet substructure (1)
- KDIGO (1)
- KPS (1)
- Knowledgebased analysis (1)
- Lactic acidosis (1)
- Landscape genetics (1)
- Laparostomy (1)
- Lehre (1)
- Lenalidomide (1)
- Library screening (1)
- Liver diseases (1)
- Liver enzymes (1)
- Liver transplantation (1)
- Load flow calculations (1)
- Long distance movement (1)
- Low volume prep (1)
- Low-molecular-weight heparin (1)
- Luciferase (1)
- Lumbar spine (1)
- Luzulo-Fagetum (1)
- Lymphoid Neoplasia (1)
- M. Intracellulare (1)
- M. avium (1)
- M. avium complex (1)
- M. chimaera (1)
- MACS (1)
- MALAT1 (1)
- MGMT (1)
- MMF (1)
- MPA (1)
- MRI (1)
- MSC-subsets (1)
- Maianthemo-Fagetum (1)
- Malaria (1)
- Marginal integrity (1)
- Marine chemistry (1)
- Material budget (1)
- Medical imaging (1)
- Medical research (1)
- Mena/VASP (1)
- Meriç River (1)
- Mesenchymal stem cells (1)
- Mesh (1)
- Metabolism (1)
- MicroRNAs (1)
- Microbiome (1)
- Microgap (1)
- Mid-rapidity (1)
- Minimal residual disease (1)
- Minimum Bias (1)
- Mitochondrial disorder (1)
- Mixed hearing loss (1)
- Mobile links (1)
- Models & methods for nuclear reactions (1)
- Molecular neuroscience (1)
- Monte Carlo (1)
- Morphological modeling (1)
- Moviprep (1)
- Multi-Parton Interactions (1)
- Multi-stakeholder approach (1)
- Multi-strange baryons (1)
- Multi-wire proportional drift chamber (1)
- Multiomics (1)
- Multiparametric MRI (1)
- Multiple myeloma (1)
- Multiple parton interactions (1)
- Myeloid Neoplasia (1)
- NADPH oxidase (1)
- NCoR1 (1)
- NK-92 (1)
- NMDA IgA/IgM antibodies (1)
- NMDA antibody (1)
- NSE (1)
- NSG mice (1)
- NTM (1)
- Natural language processing (1)
- Neoadjuvant radiochemotherapy (1)
- Neoadjuvant therapy (1)
- Neolithic (1)
- Neonatal (1)
- Net-charge correlations (1)
- Net-charge fluctuations (1)
- Network analysis (1)
- Neural network (1)
- Neuroscience (1)
- Neutron physics (1)
- Next-generation sequencing (1)
- Nf2 (1)
- Non-trauma (1)
- Non-tuberculous mycobacteria (1)
- Nonflow (1)
- Noninferiority (1)
- Nox1 (1)
- NoxO1 (1)
- Nuclear modification factor (1)
- Nuclear reactions (1)
- Nutrition (1)
- Nymphs (1)
- ORL (1)
- Obesity (1)
- Oesophagogastric cancer oxaliplatin (1)
- Oldest-old (1)
- Omics (1)
- Open abdomen (1)
- Organ allocation (1)
- Osteoporosis (1)
- Osteoporosis diagnosis (1)
- Otorhinolaryngology (1)
- Outcome (1)
- Ovarian cancer (1)
- PD-1 (1)
- PDGFRβ (1)
- PID prevalence (1)
- PRG5 (1)
- PSA screening (1)
- PSA-Screening (1)
- PTEN (1)
- PTSD (1)
- PYTHIA (1)
- Paediatric research (1)
- Palaeoceanography (1)
- Palaeoclimate (1)
- Pancreas transplantation (1)
- Pancreatitis (1)
- Parainfluenza (1)
- Parkinson disease (1)
- Parkinson's disease (1)
- Particle and Resonance Production (1)
- Particle production (1)
- Pathological complete response (1)
- Pathology (1)
- Patterns of care (1)
- Pb–Pb (1)
- Pediatric (1)
- Pediatric oncology (1)
- Pediatric stem cell transplantation (1)
- Periclymeno-Fagetum (1)
- Periodontitis (1)
- Peritoneal macrophages (1)
- Peritonitis (1)
- Personalized medicine (1)
- Phospho-soda (1)
- Phosphorylation (1)
- Physics (1)
- PillCamColon2 (1)
- Plasmodium (1)
- Pneumonia (1)
- Polyps (1)
- Posttraumatic stress disorder (1)
- Power system simulations (1)
- Pre-emptive immunotherapy (1)
- Pre-treatment drug resistance mutations (1)
- Preclinical research (1)
- Prediction (1)
- Preventive medicine (1)
- Production Cross Section (1)
- Prognosis (1)
- Prognostic markers (1)
- Prognostic models (1)
- Properties of Hadrons (1)
- Prostata-specific antigen (1)
- Prostataspezifisches Antigen (1)
- Proton-proton collisions (1)
- Proton–proton (1)
- Proton–proton collisions (1)
- Prävention (1)
- Psychiatry (1)
- Pyogenic spondylodiscitis (1)
- QGP (1)
- Quantitative features (1)
- Quark Deconfinement (1)
- Quark Gluon Plasma (1)
- Quark Production (1)
- Quark gluon plasma (1)
- Quark–gluon plasma (1)
- Quinine (1)
- RD cells (1)
- REMS (1)
- RH30 cells (1)
- RMS (1)
- RSL curve (1)
- Radiative capture (1)
- Radiomics (1)
- Rapidity Range (1)
- Re-exploration (1)
- Reactive oxygen species (1)
- Real world (1)
- Red blood cell transfusion (1)
- Rehabilitation (1)
- Reintervention (1)
- Rejection (1)
- Relapse (1)
- Relativistic heavy ion physics (1)
- Remission (1)
- Renal lesions (1)
- Research (1)
- Research Infrastructure (1)
- Residency (1)
- Resolution Parameter (1)
- Resonance reactions (1)
- Resonances (1)
- Respiratory syncytial virus (1)
- Rheumatoid arthritis (1)
- Risk factor (1)
- Rpo4/7 (1)
- Ryanodine (1)
- S100b (1)
- SARS-CoV-2 (1)
- SARS-CoV‑2 pandemic (1)
- SARS-CoV‑2-Pandemie (1)
- SKALE score (1)
- STAMPE2 (1)
- SVR (1)
- Safety (1)
- Salivary gland carcinoma (1)
- Seasonal variation (1)
- Second-line treatment (1)
- Semantics (1)
- Sensory systems (1)
- Serine proteases (1)
- Severe malaria (1)
- Shannon index (1)
- Single muons (1)
- Single-cell RNA-seq (1)
- Small molecules (1)
- SoftDrop (1)
- Solar insolation (1)
- Sorafenib (1)
- Specialist training (1)
- Species coexistence (1)
- Spectrin (1)
- Spin alignment (1)
- Spirochetes (1)
- Splitting function (1)
- Stentoplasty (1)
- Storage ring (1)
- Strangeness enhancement (1)
- Structural plasticity (1)
- Suicide (1)
- Sunlight (1)
- Superinfection (1)
- Superoxide (1)
- Surgical oncology (1)
- Sustained virological response (SVR) (1)
- Synaptopodin (1)
- Synthetic (1)
- Systematic Uncertainty (1)
- TGFB-induced factor homeobox 1 (1)
- TGIF (1)
- TOR signalling (1)
- TR (1)
- Tailored medicine (1)
- Teaching (1)
- Technical data (1)
- Technique (1)
- Teeth (1)
- Temozolomide (1)
- Temporal text analysis (1)
- Therapeutic anticoagulation (1)
- Thermal model (1)
- Time Projection Chamber (1)
- Timing (1)
- Tracking (1)
- Transient elastography (1)
- Transition radiation detector (1)
- Translational research (1)
- Transverse momentum (1)
- Transversity (1)
- Trastorno de estrés postraumático (1)
- Trauma (1)
- Treatment (1)
- Trigger (1)
- Triple negative (1)
- Triple-negative breast cancer (1)
- U2-OS (1)
- Ultrasound (1)
- University hospitals (1)
- Universitätskliniken (1)
- Upper respiratory tract infection (1)
- VEGF receptor 2 internalization and signaling (1)
- VEGFR (1)
- VEGFR-2 (1)
- VEGFR-3 (1)
- Vascular emergencies (1)
- Vasospasm (1)
- Vector Boson Production (1)
- Vertebral augmentation (1)
- Vertebral body stenting (1)
- Vertebral fracture (1)
- Vesicles (1)
- Virological failure (1)
- Vitamin (1)
- Voltage attenuation (1)
- Vorsorgeuntersuchung (1)
- WAF (1)
- Weiterbildung (1)
- WoMo score (1)
- Wound healing potential (1)
- X-ray crystallography (1)
- Xenon-based gas mixture (1)
- ZF-L (1)
- acneiform skin toxicity (1)
- acoustic radiation force impulse imaging (1)
- acute lymphoblastic leukemia (1)
- adjuvant chemotherapy (1)
- aegean (1)
- age (1)
- age-related macular degeneration (1)
- alleles (1)
- allogeneic hematological stem cell transplantation (1)
- allogeneic transplantation (1)
- ames fluctuation assay (1)
- amoxicillin/metronidazole (1)
- amphiregulin (1)
- anaemia (1)
- anaesthesia in orthopaedics (1)
- anaesthetics (1)
- anchialine cave (1)
- angiogenesis (1)
- angiopoietin-2 (1)
- angiopoietin-like 3 (ANGPTL3) (1)
- antiangiogenic therapy (1)
- antiangiogenic therapy resistance (1)
- antibiotic prophylactic therapy (1)
- antibodies (1)
- anticonvulsants (1)
- antiviral therapy (1)
- archeological sea-level limiting points (1)
- attachment loss (1)
- autism spectrum disorder (1)
- autistic disorder (1)
- autoantibodies (1)
- autoimmunity (1)
- axions (1)
- azacitidine (1)
- b-cell lymphomas (1)
- bacterial leakage (1)
- bendamustine (1)
- bioactivity testing (1)
- biobank (1)
- biogeographic legaciese (1)
- bone (1)
- bone marrow metastasis (1)
- brain metastasis (1)
- c-kit (1)
- cART (1)
- calorimeter: electromagnetic (1)
- cancer immunotherapy (1)
- cancer surveillance (1)
- cancer therapy (1)
- capture (1)
- carbon and proton assignments (1)
- cardiocerebral resuscitation (1)
- cardiopulmonary resuscitation (1)
- cell transplantation (1)
- cellular heterogeneity (1)
- cellular therapy (1)
- cerium (1)
- chemotherapy regimen (1)
- child (1)
- children and adolescents (1)
- chimeric antigen receptor (CAR) (1)
- chimeric antigen receptor t-cell therapy (1)
- chimeric antigen receptors (1)
- chromosomal aberrations (1)
- chronic viral hepatitis (1)
- clinical relevance (1)
- cluster analysis (1)
- co-infection (1)
- coastal geomorphology (1)
- cognitive-behavioral therapy (1)
- common genetic variation (1)
- conical coupling (1)
- conometric connection (1)
- copy number polymorphism (1)
- cross-section (1)
- crude oil (1)
- cryo-EM (1)
- cryopreservation (1)
- cytotoxic T cells (1)
- dE/dx (1)
- dark matter experiments (1)
- data science (1)
- debridement (1)
- detector (1)
- dexamethasone (1)
- diabetes mellitus (1)
- disease prevalence (1)
- domestication (1)
- eInfrastructure (1)
- eScience (1)
- easyPACId (1)
- ectosomes (1)
- elderly (1)
- elderly patients (1)
- electrical resistivity tomography (1)
- electronics: readout (1)
- endothelial cells (1)
- energy system simulations (1)
- ensayo controlado aleatorizado (1)
- epilepsy (1)
- epiregulin (1)
- evolution (1)
- ex vivo expansion (1)
- exosomes (1)
- experimental results (1)
- exponential model (1)
- extracellular vesicles (1)
- fibre: optical (1)
- fibrotest (1)
- follow-up (1)
- foraminifera (1)
- foraminifers (1)
- forest classification (1)
- forest functional similarity (1)
- fresh frozen plasma (1)
- gene flow (1)
- genes (1)
- genetic distance (1)
- genetic diversity (1)
- genetics (1)
- genome (1)
- genome-wide association study (1)
- genotype (1)
- genotype determination (1)
- geophysical prospections (1)
- geriatric medicine (1)
- germ cell tumors (1)
- glioblastoma survival (1)
- glioma microenvironment (1)
- graft-versus host (1)
- guidelines (1)
- habitat destruction (1)
- heavy ion experiments (1)
- heavy-ion collisions (1)
- hepatitis C (1)
- hepatitis c (1)
- high-dose chemotherapy (1)
- histology (1)
- hospital exemption (1)
- human knockout model (1)
- human olfaction (1)
- imagery rescripting (1)
- immune checkpoint blockade (1)
- immune infiltration (1)
- immune monitoring (1)
- infection precaution (1)
- inflammation (1)
- juvenile myelomonocytic leukemia (1)
- kidney function (1)
- knockout mouse (1)
- land use (1)
- lectotype (1)
- leukapheresis (1)
- liver metastasis (1)
- long non-coding RNA (1)
- long-term protection (1)
- long36 term protection (1)
- lppr5 (1)
- mRNA surveillance (1)
- machine-learning (1)
- magnetic gradiometry (1)
- malignancy (1)
- marginal fit (1)
- membrane proteins (1)
- mesenchymal stromal cell (1)
- mesenchymal stromal cells (1)
- metabolic syndrome (1)
- metastasis (1)
- micronucleus assay (1)
- micropalaeontology (1)
- microparticles (1)
- microvesicles (1)
- minimal information requirements (1)
- multiple trauma (1)
- mutation (1)
- n_TOF (1)
- natural killer cells (1)
- natural products (1)
- neuroblastoma (1)
- neurooncology (1)
- neutralizing antibodies (1)
- neutron (1)
- non-invasive fibrosis assessment (1)
- non-malignant hematological diseases (1)
- nucleosynthesis (1)
- obesity (1)
- optimal power flow (1)
- outcome parameter (1)
- ovary (1)
- oxidative stress (1)
- p+p collisions (1)
- p47phox (1)
- patients (1)
- pediatric cancer (1)
- periodontitis (1)
- peritumoral edema (1)
- peritumoral edema zone (1)
- pharmacokinetics (1)
- phenotype (1)
- phylogenetic community distance (1)
- phylogeny (1)
- platelet lysate (1)
- plppr5 (1)
- point shear wave elastography (1)
- portal hypertension (1)
- post-transplantation lymphoproliferative disease (1)
- posttraumatic inflammation (1)
- preclinical (1)
- predictive biomarkers (1)
- primary active transporters (1)
- primary biliary cholangitis (1)
- primary immunodeficiency (1)
- primary immunodeficiency (PID) (1)
- principal component analysis (1)
- prognosis (1)
- prostate cancer (1)
- proteobacteria (1)
- psoriasis (1)
- pulmonary embolism (1)
- quark gluon plasma (1)
- radio sensitivity (1)
- randomised controlled trial (1)
- randomized-controlled trial (1)
- recurrence pattern (1)
- reescritura de imágenes (1)
- refined fuels (1)
- refractory aGvHD (1)
- refugees (1)
- refugiados (1)
- registry for primary immunodeficiency (1)
- renewable energy (1)
- renin-angiotensin system (1)
- reproducibility (1)
- ribosome-associated quality control (1)
- rigor (1)
- risk prediction (1)
- rituximab (1)
- s-process (1)
- schizophrenia (1)
- sea-level indicator (1)
- second line therapy (1)
- second mitochondria-derived activator of caspases mimetic (1)
- secondary chemical shifts (1)
- secukinumab (1)
- security-constrained optimal power flow (1)
- seed and soil (1)
- seizures (1)
- sequence alignment (1)
- severe congenital neutropenia (1)
- sex (1)
- shell morphology (1)
- shortening of treatment (1)
- sickle cell anemia (1)
- simplified production (1)
- single nucleotide polymorphism (1)
- single subject classification (1)
- single-cell proteomics (1)
- soft tissue sarcoma (1)
- solar physics (1)
- solid-state NMR (1)
- spectra (1)
- sphingolipid (1)
- spike protein (1)
- spinal bone metastasis (1)
- spinal metastasis (1)
- sprouting angiogenesis (1)
- ssFLYA (1)
- stability (1)
- stage II/III colorectal cancer (1)
- standardization (1)
- steroid-resistant aGvHD (1)
- stopping rule (1)
- stroke (1)
- structural biology (1)
- subterranean ecology (1)
- sunitinib (1)
- surgery (1)
- syntaxonomy (1)
- systemic antibiotics (1)
- temporal classification (1)
- testis (1)
- thalassemia (1)
- therapeutic anticoagulation (1)
- tip cell filopodia formation (1)
- transient elastography (1)
- transplantation (1)
- trauma (1)
- traumatic brain injury (TBI) (1)
- treatment resistance (1)
- treatment response (1)
- troglobitic microsnails (1)
- tropical forests (1)
- unit commitment; (1)
- ursodeoxycholic acid (1)
- uveal melanoma (1)
- vaccination (1)
- variants of concern (1)
- vascular endothelial growth factor (1)
- white and brown dwarfs (1)
- women (1)
- Öffentlichkeit (1)
- Υ suppression (1)
- гепатит С (1)
- правила прекращения лечения (1)
- противовирусные препараты прямого действия (ПППД) (1)
- сокращение лечения (1)
- устойчивый вирусологический ответ (УВО) (1)
- √sN N = 2.76 TeV (1)
- 创伤后应激障碍 (1)
- 意向重构 (1)
- 随机对照试验 (1)
- 难民 (1)
Institute
- Physik (1196)
- Frankfurt Institute for Advanced Studies (FIAS) (1071)
- Informatik (925)
- Medizin (181)
- Geowissenschaften (23)
- Biowissenschaften (6)
- Informatik und Mathematik (6)
- Senckenbergische Naturforschende Gesellschaft (6)
- Biochemie und Chemie (5)
- Institut für Ökologie, Evolution und Diversität (5)
We report the measurement of K∗0 meson at midrapidity (|y|< 1.0) in Au+Au collisions at sNN−−−√~=~7.7, 11.5, 14.5, 19.6, 27 and 39 GeV collected by the STAR experiment during the RHIC beam energy scan (BES) program. The transverse momentum spectra, yield, and average transverse momentum of K∗0 are presented as functions of collision centrality and beam energy. The K∗0/K yield ratios are presented for different collision centrality intervals and beam energies. The K∗0/K ratio in heavy-ion collisions are observed to be smaller than that in small system collisions (e+e and p+p). The K∗0/K ratio follows a similar centrality dependence to that observed in previous RHIC and LHC measurements. The data favor the scenario of the dominance of hadronic re-scattering over regeneration for K∗0 production in the hadronic phase of the medium.
We report a measurement of cumulants and correlation functions of event-by-event proton multiplicity distributions from fixed-target Au+Au collisions at sNN−−−√ = 3 GeV measured by the STAR experiment. Protons are identified within the rapidity (y) and transverse momentum (pT) region −0.9<y<0 and 0.4<pT<2.0 GeV/c in the center-of-mass frame. A systematic analysis of the proton cumulants and correlation functions up to sixth-order as well as the corresponding ratios as a function of the collision centrality, pT, and y are presented. The effect of pileup and initial volume fluctuations on these observables and the respective corrections are discussed in detail. The results are compared to calculations from the hadronic transport UrQMD model as well as a hydrodynamic model. In the most central 5\% collisions, the value of proton cumulant ratio C4/C2 is negative, drastically different from the values observed in Au+Au collisions at higher energies. Compared to model calculations including Lattice QCD, a hadronic transport model, and a hydrodynamic model, the strong suppression in the ratio of C4/C2 at 3 GeV Au+Au collisions indicates an energy regime dominated by hadronic interactions.
A decisive experimental test of the Chiral Magnetic Effect (CME) is considered one of the major scientific goals at the Relativistic Heavy-Ion Collider (RHIC) towards understanding the nontrivial topological fluctuations of the Quantum Chromodynamics vacuum. In heavy-ion collisions, the CME is expected to result in a charge separation phenomenon across the reaction plane, whose strength could be strongly energy dependent. The previous CME searches have been focused on top RHIC energy collisions. In this Letter, we present a low energy search for the CME in Au+Au collisions at sNN−−−√=27 GeV. We measure elliptic flow scaled charge-dependent correlators relative to the event planes that are defined at both mid-rapidity |η|<1.0 and at forward rapidity 2.1<|η|<5.1. We compare the results based on the directed flow plane (Ψ1) at forward rapidity and the elliptic flow plane (Ψ2) at both central and forward rapidity. The CME scenario is expected to result in a larger correlation relative to Ψ1 than to Ψ2, while a flow driven background scenario would lead to a consistent result for both event planes. In 10-50\% centrality, results using three different event planes are found to be consistent within experimental uncertainties, suggesting a flow driven background scenario dominating the measurement. We obtain an upper limit on the deviation from a flow driven background scenario at the 95\% confidence level. This work opens up a possible road map towards future CME search with the high statistics data from the RHIC Beam Energy Scan Phase-II.
A decisive experimental test of the Chiral Magnetic Effect (CME) is considered one of the major scientific goals at the Relativistic Heavy-Ion Collider (RHIC) towards understanding the nontrivial topological fluctuations of the Quantum Chromodynamics vacuum. In heavy-ion collisions, the CME is expected to result in a charge separation phenomenon across the reaction plane, whose strength could be strongly energy dependent. The previous CME searches have been focused on top RHIC energy collisions. In this Letter, we present a low energy search for the CME in Au+Au collisions at sNN−−−√=27 GeV. We measure elliptic flow scaled charge-dependent correlators relative to the event planes that are defined at both mid-rapidity |η|<1.0 and at forward rapidity 2.1<|η|<5.1. We compare the results based on the directed flow plane (Ψ1) at forward rapidity and the elliptic flow plane (Ψ2) at both central and forward rapidity. The CME scenario is expected to result in a larger correlation relative to Ψ1 than to Ψ2, while a flow driven background scenario would lead to a consistent result for both event planes. In 10-50\% centrality, results using three different event planes are found to be consistent within experimental uncertainties, suggesting a flow driven background scenario dominating the measurement. We obtain an upper limit on the deviation from a flow driven background scenario at the 95\% confidence level. This work opens up a possible road map towards future CME search with the high statistics data from the RHIC Beam Energy Scan Phase-II.
Azimuthal anisotropy measurement of (multi-)strange hadrons in Au+Au collisions at √sNN = 54.4 GeV
(2023)
Azimuthal anisotropy of produced particles is one of the most important observables used to access the collective properties of the expanding medium created in relativistic heavy-ion collisions. In this paper, we present second (v2) and third (v3) order azimuthal anisotropies of K0S, ϕ, Λ, Ξ and Ω at mid-rapidity (|y|<1) in Au+Au collisions at sNN−−−√ = 54.4 GeV measured by the STAR detector. The v2 and v3 are measured as a function of transverse momentum and centrality. Their energy dependence is also studied. v3 is found to be more sensitive to the change in the center-of-mass energy than v2. Scaling by constituent quark number is found to hold for v2 within 10%. This observation could be evidence for the development of partonic collectivity in 54.4 GeV Au+Au collisions. Differences in v2 and v3 between baryons and anti-baryons are presented, and ratios of v3/v3/22 are studied and motivated by hydrodynamical calculations. The ratio of v2 of ϕ mesons to that of anti-protons (v2(ϕ)/v2(p¯)) shows centrality dependence at low transverse momentum, presumably resulting from the larger effects from hadronic interactions on anti-proton v2.
In relativistic heavy-ion collisions, a global spin polarization, PH, of Λ and Λ¯ hyperons along the direction of the system angular momentum was discovered and measured across a broad range of collision energies and demonstrated a trend of increasing PH with decreasing sNN−−−√. A splitting between Λ and Λ¯ polarization may be possible due to their different magnetic moments in a late-stage magnetic field sustained by the quark-gluon plasma which is formed in the collision. The results presented in this study find no significant splitting at the collision energies of sNN−−−√=19.6 and 27 GeV in the RHIC Beam Energy Scan Phase II using the STAR detector, with an upper limit of PΛ¯−PΛ<0.24% and PΛ¯−PΛ<0.35%, respectively, at a 95% confidence level. We derive an upper limit on the naïve extraction of the late-stage magnetic field of B<9.4⋅1012 T and B<1.4⋅1013 T at sNN−−−√=19.6 and 27 GeV, respectively, although more thorough derivations are needed. Differential measurements of PH were performed with respect to collision centrality, transverse momentum, and rapidity. With our current acceptance of |y|<1 and uncertainties, we observe no dependence on transverse momentum and rapidity in this analysis. These results challenge multiple existing model calculations following a variety of different assumptions which have each predicted a strong dependence on rapidity in this collision-energy range.
In relativistic heavy-ion collisions, a global spin polarization, PH, of Λ and Λ¯ hyperons along the direction of the system angular momentum was discovered and measured across a broad range of collision energies and demonstrated a trend of increasing PH with decreasing sNN−−−√. A splitting between Λ and Λ¯ polarization may be possible due to their different magnetic moments in a late-stage magnetic field sustained by the quark-gluon plasma which is formed in the collision. The results presented in this study find no significant splitting at the collision energies of sNN−−−√=19.6 and 27 GeV in the RHIC Beam Energy Scan Phase II using the STAR detector, with an upper limit of PΛ¯−PΛ<0.24% and PΛ¯−PΛ<0.35%, respectively, at a 95% confidence level. We derive an upper limit on the naïve extraction of the late-stage magnetic field of B<9.4⋅1012 T and B<1.4⋅1013 T at sNN−−−√=19.6 and 27 GeV, respectively, although more thorough derivations are needed. Differential measurements of PH were performed with respect to collision centrality, transverse momentum, and rapidity. With our current acceptance of |y|<1 and uncertainties, we observe no dependence on transverse momentum and rapidity in this analysis. These results challenge multiple existing model calculations following a variety of different assumptions which have each predicted a strong dependence on rapidity in this collision-energy range.
In relativistic heavy-ion collisions, a global spin polarization, PH, of Λ and Λ¯ hyperons along the direction of the system angular momentum was discovered and measured across a broad range of collision energies and demonstrated a trend of increasing PH with decreasing sNN−−−√. A splitting between Λ and Λ¯ polarization may be possible due to their different magnetic moments in a late-stage magnetic field sustained by the quark-gluon plasma which is formed in the collision. The results presented in this study find no significant splitting at the collision energies of sNN−−−√=19.6 and 27 GeV in the RHIC Beam Energy Scan Phase II using the STAR detector, with an upper limit of PΛ¯−PΛ<0.24% and PΛ¯−PΛ<0.35%, respectively, at a 95% confidence level. We derive an upper limit on the naïve extraction of the late-stage magnetic field of B<9.4⋅1012 T and B<1.4⋅1013 T at sNN−−−√=19.6 and 27 GeV, respectively, although more thorough derivations are needed. Differential measurements of PH were performed with respect to collision centrality, transverse momentum, and rapidity. With our current acceptance of |y|<1 and uncertainties, we observe no dependence on transverse momentum and rapidity in this analysis. These results challenge multiple existing model calculations following a variety of different assumptions which have each predicted a strong dependence on rapidity in this collision-energy range.
A decisive experimental test of the Chiral Magnetic Effect (CME) is considered one of the major scientific goals at the Relativistic Heavy-Ion Collider (RHIC) towards understanding the nontrivial topological fluctuations of the Quantum Chromodynamics vacuum. In heavy-ion collisions, the CME is expected to result in a charge separation phenomenon across the reaction plane, whose strength could be strongly energy dependent. The previous CME searches have been focused on top RHIC energy collisions. In this Letter, we present a low energy search for the CME in Au+Au collisions at sNN−−−√=27 GeV. We measure elliptic flow scaled charge-dependent correlators relative to the event planes that are defined at both mid-rapidity |η|<1.0 and at forward rapidity 2.1<|η|<5.1. We compare the results based on the directed flow plane (Ψ1) at forward rapidity and the elliptic flow plane (Ψ2) at both central and forward rapidity. The CME scenario is expected to result in a larger correlation relative to Ψ1 than to Ψ2, while a flow driven background scenario would lead to a consistent result for both event planes. In 10-50\% centrality, results using three different event planes are found to be consistent within experimental uncertainties, suggesting a flow driven background scenario dominating the measurement. We obtain an upper limit on the deviation from a flow driven background scenario at the 95\% confidence level. This work opens up a possible road map towards future CME search with the high statistics data from the RHIC Beam Energy Scan Phase-II.
We report the beam energy and collision centrality dependence of fifth and sixth order cumulants (C5, C6) and factorial cumulants (κ5, κ6) of net-proton and proton distributions, from sNN−−−−√=3−200 GeV Au+Au collisions at RHIC. The net-proton cumulant ratios generally follow the hierarchy expected from QCD thermodynamics, except for the case of collisions at sNN−−−−√ = 3 GeV. C6/C2 for 0-40\% centrality collisions is increasingly negative with decreasing sNN−−−−√, while it is positive for the lowest sNN−−−−√ studied. These observed negative signs are consistent with QCD calculations (at baryon chemical potential, μB≤ 110 MeV) that include a crossover quark-hadron transition. In addition, for sNN−−−−√≥ 11.5 GeV, the measured proton κn, within uncertainties, does not support the two-component shape of proton distributions that would be expected from a first-order phase transition. Taken in combination, the hyper-order proton number fluctuations suggest that the structure of QCD matter at high baryon density, μB∼750 MeV (sNN−−−−√ = 3 GeV) is starkly different from those at vanishing μB∼20MeV (sNN−−−−√ = 200 GeV and higher).
We report on measurements of sequential Υ suppression in Au+Au collisions at sNN−−−√ = 200 GeV with the STAR detector at the Relativistic Heavy Ion Collider (RHIC) through both the dielectron and dimuon decay channels. In the 0-60% centrality class, the nuclear modification factors (RAA), which quantify the level of yield suppression in heavy-ion collisions compared to p+p collisions, for Υ(1S) and Υ(2S) are 0.40±0.03 (stat.)±0.03 (sys.)±0.09 (norm.) and 0.26±0.08 (stat.)±0.02 (sys.)±0.06 (norm.), respectively, while the upper limit of the Υ(3S) RAA is 0.17 at a 95% confidence level. This provides experimental evidence that the Υ(3S) is significantly more suppressed than the Υ(1S) at RHIC. The level of suppression for Υ(1S) is comparable to that observed at the much higher collision energy at the Large Hadron Collider. These results point to the creation of a medium at RHIC whose temperature is sufficiently high to strongly suppress excited Υ states.
Measurements of mass and Λ binding energy of 4ΛH and 4ΛHe in Au+Au collisions at sNN−−−√=3 GeV are presented, with an aim to address the charge symmetry breaking (CSB) problem in hypernuclei systems with atomic number A = 4. The Λ binding energies are measured to be 2.22±0.06(stat.)±0.14(syst.) MeV and 2.38±0.13(stat.)±0.12(syst.) MeV for 4ΛH and 4ΛHe, respectively. The measured Λ binding-energy difference is 0.16±0.14(stat.)±0.10(syst.) MeV for ground states. Combined with the γ-ray transition energies, the binding-energy difference for excited states is −0.16±0.14(stat.)±0.10(syst.) MeV, which is negative and comparable to the value of the ground states within uncertainties. These new measurements on the Λ binding-energy difference in A = 4 hypernuclei systems are consistent with the theoretical calculations that result in ΔB4Λ(1+exc)≈−ΔB4Λ(0+g.s.)<0 and present a new method for the study of CSB effect using relativistic heavy-ion collisions.
Measurements of mass and Λ binding energy of 4ΛH and 4ΛHe in Au+Au collisions at sNN−−−√=3 GeV are presented, with an aim to address the charge symmetry breaking (CSB) problem in hypernuclei systems with atomic number A = 4. The Λ binding energies are measured to be 2.22±0.06(stat.)±0.14(syst.) MeV and 2.38±0.13(stat.)±0.12(syst.) MeV for 4ΛH and 4ΛHe, respectively. The measured Λ binding-energy difference is 0.16±0.14(stat.)±0.10(syst.) MeV for ground states. Combined with the γ-ray transition energies, the binding-energy difference for excited states is −0.16±0.14(stat.)±0.10(syst.) MeV, which is negative and comparable to the value of the ground states within uncertainties. These new measurements on the Λ binding-energy difference in A = 4 hypernuclei systems are consistent with the theoretical calculations that result in ΔB4Λ(1+exc)≈−ΔB4Λ(0+g.s.)<0 and present a new method for the study of CSB effect using relativistic heavy-ion collisions.
Measurements of mass and Λ binding energy of 4ΛH and 4ΛHe in Au+Au collisions at sNN−−−√=3 GeV are presented, with an aim to address the charge symmetry breaking (CSB) problem in hypernuclei systems with atomic number A = 4. The Λ binding energies are measured to be 2.22±0.06(stat.)±0.14(syst.) MeV and 2.38±0.13(stat.)±0.12(syst.) MeV for 4ΛH and 4ΛHe, respectively. The measured Λ binding-energy difference is 0.16±0.14(stat.)±0.10(syst.) MeV for ground states. Combined with the γ-ray transition energies, the binding-energy difference for excited states is −0.16±0.14(stat.)±0.10(syst.) MeV, which is negative and comparable to the value of the ground states within uncertainties. These new measurements on the Λ binding-energy difference in A = 4 hypernuclei systems are consistent with the theoretical calculations that result in ΔB4Λ(1+exc)≈−ΔB4Λ(0+g.s.)<0 and present a new method for the study of CSB effect using relativistic heavy-ion collisions.
A linearly polarized photon can be quantized from the Lorentz-boosted electromagnetic field of a nucleus traveling at ultrarelativistic speed. When two relativistic heavy nuclei pass one another at a distance of a few nuclear radii, the photon from one nucleus may interact through a virtual quark-antiquark pair with gluons from the other nucleus, forming a short-lived vector meson (e.g., ρ0). In this experiment, the polarization was used in diffractive photoproduction to observe a unique spin interference pattern in the angular distribution of ρ0 → π+π− decays. The observed interference is a result of an overlap of two wave functions at a distance an order of magnitude larger than the ρ0 travel distance within its lifetime. The strong-interaction nuclear radii were extracted from these diffractive interactions and found to be 6.53 ± 0.06 fm (197Au) and 7.29 ± 0.08 fm (238U), larger than the nuclear charge radii. The observable is demonstrated to be sensitive to the nuclear geometry and quantum interference of nonidentical particles. Polarized photon-gluon fusion reveals quantum wave interference of non-identical particles and shape of high-energy nuclei.
Partons traversing the strongly interacting medium produced in heavy-ion collisions are expected to lose energy depending on their color charge and mass. We measure the nuclear modification factors for charm- and bottom-decay electrons, defined as the ratio of yields, scaled by the number of binary nucleon-nucleon collisions, in sNN−−−√ = 200 GeV Au+Au collisions to p+p collisions (RAA), or in central to peripheral Au+Au collisions (RCP). We find the bottom-decay electron RAA and RCP to be significantly higher than that of charm-decay electrons. Model calculations including mass-dependent parton energy loss in a strongly coupled medium are consistent with the measured data. These observations provide clear evidence of mass ordering of charm and bottom quark energy loss when traversing through the strongly coupled medium created in heavy-ion collisions.
Partons traversing the strongly interacting medium produced in heavy-ion collisions are expected to lose energy depending on their color charge and mass. We measure the nuclear modification factors for charm- and bottom-decay electrons, defined as the ratio of yields, scaled by the number of binary nucleon-nucleon collisions, in sNN−−−√ = 200 GeV Au+Au collisions to p+p collisions (RAA), or in central to peripheral Au+Au collisions (RCP). We find the bottom-decay electron RAA and RCP to be significantly higher than that of charm-decay electrons. Model calculations including mass-dependent parton energy loss in a strongly coupled medium are consistent with the measured data. These observations provide clear evidence of mass ordering of charm and bottom quark energy loss when traversing through the strongly coupled medium created in heavy-ion collisions.
Partons traversing the strongly interacting medium produced in heavy-ion collisions are expected to lose energy depending on their color charge and mass. We measure the nuclear modification factors for charm- and bottom-decay electrons, defined as the ratio of yields, scaled by the number of binary nucleon-nucleon collisions, in sNN−−−√ = 200 GeV Au+Au collisions to p+p collisions (RAA), or in central to peripheral Au+Au collisions (RCP). We find the bottom-decay electron RAA and RCP to be significantly higher than that of charm-decay electrons. Model calculations including mass-dependent parton energy loss in a strongly coupled medium are consistent with the measured data. These observations provide clear evidence of mass ordering of charm and bottom quark energy loss when traversing through the strongly coupled medium created in heavy-ion collisions.
Partons traversing the strongly interacting medium produced in heavy-ion collisions are expected to lose energy depending on their color charge and mass. We measure the nuclear modification factors for charm- and bottom-decay electrons, defined as the ratio of yields, scaled by the number of binary nucleon-nucleon collisions, in sNN−−−√ = 200 GeV Au+Au collisions to p+p collisions (RAA), or in central to peripheral Au+Au collisions (RCP). We find the bottom-decay electron RAA and RCP to be significantly higher than that of charm-decay electrons. Model calculations including mass-dependent parton energy loss in a strongly coupled medium are consistent with the measured data. These observations provide clear evidence of mass ordering of charm and bottom quark energy loss when traversing through the strongly coupled medium created in heavy-ion collisions.
Partons traversing the strongly interacting medium produced in heavy-ion collisions are expected to lose energy depending on their color charge and mass. We measure the nuclear modification factors for charm- and bottom-decay electrons, defined as the ratio of yields, scaled by the number of binary nucleon-nucleon collisions, in sNN−−−√ = 200 GeV Au+Au collisions to p+p collisions (RAA), or in central to peripheral Au+Au collisions (RCP). We find the bottom-decay electron RAA and RCP to be significantly higher than that of charm-decay electrons. Model calculations including mass-dependent parton energy loss in a strongly coupled medium are consistent with the measured data. These observations provide clear evidence of mass ordering of charm and bottom quark energy loss when traversing through the strongly coupled medium created in heavy-ion collisions.
We report a new measurement of the production of electrons from open heavy-flavor hadron decays (HFEs) at mid-rapidity (|y| < 0.7) in Au+Au collisions at √sNN = 200 GeV. Invariant yields of HFEs are measured for the transverse momentum range of 3.5 < pT < 9 GeV/c in various configurations of the collision geometry. The HFE yields in head-on Au+Au collisions are suppressed by approximately a factor of 2 compared to that in p + p collisions scaled by the average number of binary collisions, indicating strong interactions between heavy quarks and the hot and dense medium created in heavy-ion collisions. Comparison of these results with models provides additional tests of theoretical calculations of heavy quark energy loss in the quark-gluon plasma.
Elliptic flow of heavy-flavor decay electrons in Au+Au collisions at √sNN = 27 and 54.4 GeV at RHIC
(2023)
We report on new measurements of elliptic flow (v2) of electrons from heavy-flavor hadron decays at mid-rapidity (|y|<0.8) in Au+Au collisions at sNN−−−√ = 27 and 54.4 GeV from the STAR experiment. Heavy-flavor decay electrons (eHF) in Au+Au collisions at sNN−−−√ = 54.4 GeV exhibit a non-zero v2 in the transverse momentum (pT) region of pT< 2 GeV/c with the magnitude comparable to that at sNN−−−√=200 GeV. The measured eHF v2 at 54.4 GeV is also consistent with the expectation of their parent charm hadron v2 following number-of-constituent-quark scaling as other light and strange flavor hadrons at this energy. These suggest that charm quarks gain significant collectivity through the evolution of the QCD medium and may reach local thermal equilibrium in Au+Au collisions at sNN−−−√=54.4 GeV. The measured eHF v2 in Au+Au collisions at sNN−−−√= 27 GeV is consistent with zero within large uncertainties. The energy dependence of v2 for different flavor particles (π,ϕ,D0/eHF) shows an indication of quark mass hierarchy in reaching thermalization in high-energy nuclear collisions.
Elliptic flow of heavy-flavor decay electrons in Au+Au collisions at √sNN = 27 and 54.4 GeV at RHIC
(2023)
We report on new measurements of elliptic flow (v2) of electrons from heavy-flavor hadron decays at mid-rapidity (|y|<0.8) in Au+Au collisions at sNN−−−√ = 27 and 54.4 GeV from the STAR experiment. Heavy-flavor decay electrons (eHF) in Au+Au collisions at sNN−−−√ = 54.4 GeV exhibit a non-zero v2 in the transverse momentum (pT) region of pT< 2 GeV/c with the magnitude comparable to that at sNN−−−√=200 GeV. The measured eHF v2 at 54.4 GeV is also consistent with the expectation of their parent charm hadron v2 following number-of-constituent-quark scaling as other light and strange flavor hadrons at this energy. These suggest that charm quarks gain significant collectivity through the evolution of the QCD medium and may reach local thermal equilibrium in Au+Au collisions at sNN−−−√=54.4 GeV. The measured eHF v2 in Au+Au collisions at sNN−−−√= 27 GeV is consistent with zero within large uncertainties. The energy dependence of v2 for different flavor particles (π,ϕ,D0/eHF) shows an indication of quark mass hierarchy in reaching thermalization in high-energy nuclear collisions.
Density fluctuations near the QCD critical point can be probed via an intermittency analysis in relativistic heavy-ion collisions. We report the first measurement of intermittency in Au+Au collisions at sNN−−−√ = 7.7-200 GeV measured by the STAR experiment at the Relativistic Heavy Ion Collider (RHIC). The scaled factorial moments of identified charged hadrons are analyzed at mid-rapidity and within the transverse momentum phase space. We observe a power-law behavior of scaled factorial moments in Au+Au collisions and a decrease in the extracted scaling exponent (ν) from peripheral to central collisions. The ν is consistent with a constant for different collisions energies in the mid-central (10-40\%) collisions. Moreover, the ν in the 0-5\% most central Au+Au collisions exhibits a non-monotonic energy dependence that reaches a possible minimum around sNN−−−√ = 27 GeV. The physics implications on the QCD phase structure are discussed.
Density fluctuations near the QCD critical point can be probed via an intermittency analysis in relativistic heavy-ion collisions. We report the first measurement of intermittency in Au+Au collisions at √sNN = 7.7-200 GeV measured by the STAR experiment at the Relativistic Heavy Ion Collider (RHIC). The scaled factorial moments of identified charged hadrons are analyzed at mid-rapidity and within the transverse momentum phase space. We observe a power-law behavior of scaled factorial moments in Au+Au collisions and a decrease in the extracted scaling exponent (ν) from peripheral to central collisions. The ν is consistent with a constant for different collisions energies in the mid-central (10-40%) collisions. Moreover, the ν in the 0-5% most central Au+Au collisions exhibits a non-monotonic energy dependence that reaches a minimum around √sNN = 27 GeV. The physics implications on the QCD phase structure are discussed.
The longitudinal and transverse spin transfers to Λ (Λ¯¯¯¯) hyperons in polarized proton-proton collisions are expected to be sensitive to the helicity and transversity distributions, respectively, of (anti-)strange quarks in the proton, and to the corresponding polarized fragmentation functions. We report improved measurements of the longitudinal spin transfer coefficient, DLL, and the transverse spin transfer coefficient, DTT, to Λ and Λ¯¯¯¯ in polarized proton-proton collisions at s√ = 200 GeV by the STAR experiment at RHIC. The data set includes longitudinally polarized proton-proton collisions with an integrated luminosity of 52 pb−1, and transversely polarized proton-proton collisions with a similar integrated luminosity. Both data sets have about twice the statistics of previous results and cover a kinematic range of |ηΛ(Λ¯¯¯¯)| < 1.2 and transverse momentum pT,Λ(Λ¯¯¯¯) up to 8 GeV/c. We also report the first measurements of the hyperon spin transfer coefficients DLL and DTT as a function of the fractional jet momentum z carried by the hyperon, which can provide more direct constraints on the polarized fragmentation functions.
We report the first measurements of cumulants, up to 4𝑡ℎ order, of deuteron number distributions and protondeuteron correlations in Au+Au collisions recorded by the STAR experiment in phase-I of Beam Energy Scan (BES) program at the Relativistic Heavy Ion Collider. Deuteron cumulants, their ratios, and proton-deuteron mixed cumulants are presented for different collision centralities covering a range of center-of-mass energy per nucleon pair √𝑠NN = 7.7 to 200 GeV. It is found that the cumulant ratios at lower collision energies favor a canonical ensemble over a grand canonical ensemble in thermal models. An anti-correlation between proton and deuteron multiplicity is observed across all collision energies and centralities, consistent with the expectation from global baryon number conservation. The UrQMD model coupled with a phase-space coalescence mechanism qualitatively reproduces the collision-energy dependence of cumulant ratios and proton-deuteron correlations.
We report results on an elastic cross section measurement in proton-proton collisions at a center-of-mass energy s√=510 GeV, obtained with the Roman Pot setup of the STAR experiment at the Relativistic Heavy Ion Collider (RHIC). The elastic differential cross section is measured in the four-momentum transfer squared range 0.23≤−t≤0.67 GeV2. We find that a constant slope B does not fit the data in the aforementioned t range, and we obtain a much better fit using a second-order polynomial for B(t). The t dependence of B is determined using six subintervals of t in the STAR measured t range, and is in good agreement with the phenomenological models. The measured elastic differential cross section dσ/dt agrees well with the results obtained at s√=546 GeV for proton--antiproton collisions by the UA4 experiment. We also determine that the integrated elastic cross section within the STAR t-range is σfidel=462.1±0.9(stat.)±1.1(syst.)±11.6(scale) μb.
We report results on an elastic cross section measurement in proton-proton collisions at a center-of-mass energy s√=510 GeV, obtained with the Roman Pot setup of the STAR experiment at the Relativistic Heavy Ion Collider (RHIC). The elastic differential cross section is measured in the four-momentum transfer squared range 0.23≤−t≤0.67 GeV2. We find that a constant slope B does not fit the data in the aforementioned t range, and we obtain a much better fit using a second-order polynomial for B(t). The t dependence of B is determined using six subintervals of t in the STAR measured t range, and is in good agreement with the phenomenological models. The measured elastic differential cross section dσ/dt agrees well with the results obtained at s√=546 GeV for proton--antiproton collisions by the UA4 experiment. We also determine that the integrated elastic cross section within the STAR t-range is σfidel=462.1±0.9(stat.)±1.1(syst.)±11.6(scale) μb.
We report a new measurement of the production of electrons from open heavy-flavor hadron decays (HFEs) at mid-rapidity (|y|< 0.7) in Au+Au collisions at sNN−−−√=200 GeV. Invariant yields of HFEs are measured for the transverse momentum range of 3.5<pT<9 GeV/c in various configurations of the collision geometry. The HFE yields in head-on Au+Au collisions are suppressed by approximately a factor of 2 compared to that in p+p collisions scaled by the average number of binary collisions, indicating strong interactions between heavy quarks and the hot and dense medium created in heavy-ion collisions. Comparison of these results with models provides additional tests of theoretical calculations of heavy quark energy loss in the quark-gluon plasma.
In high-energy heavy-ion collisions, partonic collectivity is evidenced by the constituent quark number scaling of elliptic flow anisotropy for identified hadrons. A breaking of this scaling and dominance of baryonic interactions is found for identified hadron collective flow measurements in sNN−−−√ = 3 GeV Au+Au collisions. In this paper, we report measurements of the first- and second-order azimuthal anisotropic parameters, v1 and v2, of light nuclei (d, t, 3He, 4He) produced in sNN−−−√ = 3 GeV Au+Au collisions at the STAR experiment. An atomic mass number scaling is found in the measured v1 slopes of light nuclei at mid-rapidity. For the measured v2 magnitude, a strong rapidity dependence is observed. Unlike v2 at higher collision energies, the v2 values at mid-rapidity for all light nuclei are negative and no scaling is observed with the atomic mass number. Calculations by the Jet AA Microscopic Transport Model (JAM), with baryonic mean-field plus nucleon coalescence, are in good agreement with our observations, implying baryonic interactions dominate the collective dynamics in 3 GeV Au+Au collisions at RHIC.
We measure triangular flow relative to the reaction plane at 3 GeV center-of-mass energy in Au+Au collisions at the BNL Relativistic Heavy Ion Collider. A significant v3 signal for protons is observed, which increases for higher rapidity, higher transverse momentum, and more peripheral collisions. The triangular flow is essentially rapidity-odd with a slope at mid-rapidity, dv3/dy|(y=0), opposite in sign compared to the slope for directed flow. No significant v3 signal is observed for charged pions and kaons. Comparisons with models suggest that a mean field potential is required to describe these results, and that the triangular shape of the participant nucleons is the result of stopping and nuclear geometry.
We report cumulants of the proton multiplicity distribution from dedicated fixed-target Au+Au collisions at sNN−−−√ = 3.0 GeV, measured by the STAR experiment in the kinematic acceptance of rapidity (y) and transverse momentum (pT) within −0.5<y<0 and 0.4<pT<2.0 GeV/c. In the most central 0--5\% collisions, a proton cumulant ratio is measured to be C4/C2=−0.85±0.09 (stat.)±0.82 (syst.), which is less than unity, the Poisson baseline. The hadronic transport UrQMD model reproduces our C4/C2 in the measured acceptance. Compared to higher energy results and the transport model calculations, the suppression in C4/C2 is consistent with fluctuations driven by baryon number conservation and indicates an energy regime dominated by hadronic interactions. These data imply that the QCD critical region, if created in heavy-ion collisions, could only exist at energies higher than 3\,GeV.
In high-energy heavy-ion collisions, partonic collectivity is evidenced by the constituent quark number scaling of elliptic flow anisotropy for identified hadrons. A breaking of this scaling and dominance of baryonic interactions is found for identified hadron collective flow measurements in sNN−−−√ = 3 GeV Au+Au collisions. In this paper, we report measurements of the first-order and second-order azimuthal anisotropic parameters, v1 and v2, of light nuclei (d, t, 3He, 4He) produced in sNN−−−√ = 3 GeV Au+Au collisions at the STAR experiment. An atomic mass number scaling is found in the measured v1 slopes of light nuclei at mid-rapidity. For the measured v2 magnitude, a strong rapidity dependence is observed. Unlike v2 at higher collision energies, the v2 values at mid-rapidity for all light nuclei are negative and no scaling is observed with the atomic mass number. Calculations by the Jet AA Microscopic Transport Model (JAM), with baryonic mean-field plus nucleon coalescence, are in good agreement with our observations, implying baryonic interactions dominate the collective dynamics in 3 GeV Au+Au collisions at RHIC.
We report the first measurements of cumulants, up to 4th order, of deuteron number distributions and proton-deuteron correlations in Au+Au collisions recorded by the STAR experiment in phase-I of Beam Energy Scan (BES) program at the Relativistic Heavy Ion Collider. Deuteron cumulants, their ratios, and proton-deuteron mixed cumulants are presented for different collision centralities covering a range of center-of-mass energy per nucleon pair sNN−−−−√~=~7.7 to 200~GeV. It is found that the cumulant ratios at lower collision energies favor a canonical ensemble over a grand canonical ensemble in thermal models. An anti-correlation between proton and deuteron multiplicity is observed across all collision energies and centralities, consistent with the expectation from global baryon number conservation. The UrQMD model coupled with a phase-space coalescence mechanism qualitatively reproduces the collision-energy dependence of cumulant ratios and proton-deuteron correlations.
Jet-hadron correlations with respect to the event plane in √sNN = 200 GeV Au+Au collisions in STAR
(2024)
Angular distributions of charged particles relative to jet axes are studied in sNN−−−√ = 200 GeV Au+Au collisions as a function of the jet orientation with respect to the event plane. This differential study tests the expected path-length dependence of energy loss experienced by a hard-scattered parton as it traverses the hot and dense medium formed in heavy-ion collisions. A second-order event plane is used in the analysis as an experimental estimate of the reaction plane formed by the collision impact parameter and the beam direction. Charged-particle jets with 15<pT,jet< 20 and 20<pT,jet< 40 GeV/c were reconstructed with the anti-kT algorithm with radius parameter setting of (R=0.4) in the 20-50\% centrality bin to maximize the initial-state eccentricity of the interaction region. The reaction plane fit method is implemented to remove the flow-modulated background with better precision than prior methods. Yields and widths of jet-associated charged-hadron distributions are extracted in three angular bins between the jet axis and the event plane. The event-plane (EP) dependence is further quantified by ratios of the associated yields in different EP bins. No dependence on orientation of the jet axis with respect to the event plane is seen within the uncertainties in the kinematic regime studied. This finding is consistent with a similar experimental observation by ALICE in sNN−−−√ = 2.76 TeV Pb+Pb collision data.
We report a new measurement of the production of electrons from open heavy-flavor hadron decays (HFEs) at mid-rapidity (|y|< 0.7) in Au+Au collisions at sNN−−−√=200 GeV. Invariant yields of HFEs are measured for the transverse momentum range of 3.5<pT<9 GeV/c in various configurations of the collision geometry. The HFE yields in head-on Au+Au collisions are suppressed by approximately a factor of 2 compared to that in p+p collisions scaled by the average number of binary collisions, indicating strong interactions between heavy quarks and the hot and dense medium created in heavy-ion collisions. Comparison of these results with models provides additional tests of theoretical calculations of heavy quark energy loss in the quark-gluon plasma.
Background: This phase I/II-trial assessed the dose-limiting toxicities (DLT) and maximum tolerated dose (MTD) of neoadjuvant radiochemotherapy (RCT) with docetaxel and oxaliplatin in patients with locally advanced adenocarcinoma of the oesophagogastric junction.
Methods: Patients received neoadjuvant radiotherapy (50.4 Gy) together with weekly docetaxel (20 mg/m2 at dose level (DL) 1 and 2, 25 mg/m2 at DL 3) and oxaliplatin (40 mg/m2 at DL 1, 50 mg/m2 at DL 2 and 3) over 5 weeks. The primary endpoint was the DLT and the MTD of the RCT regimen. Secondary endpoints included overall response rate (ORR) and progression-free survival (PFS).
Results: A total of 24 patients were included. Four patients were treated at DL 1, 13 patients at DL 2 and 7 patients at DL 3. The MTD of the RCT was considered DL 2 with docetaxel 20 mg/m2 and oxaliplatin 50 mg/m2. Objective response (CR/PR) was observed in 32% (7/22) of patients. Eighteen patients (75%) underwent surgery after RCT. The median PFS for all patients (n = 24) was 6.5 months. The median overall survival for all patients (n = 24) was 16.3 months. Patients treated at DL 2 had a median overall survival of 29.5 months.
Conclusion: Neoadjuvant RCT with docetaxel 20 mg/m2 and oxaliplatin 50 mg/m2 was effective and showed a good toxicity profile. Future studies should consider the addition of targeted therapies to current neoadjuvant therapy regimens to further improve the outcome of patients with advanced cancer of the oesophagogastric junction.
Trial Registration: NCT00374985
Die Fundmeldungen in Band 33 von Botanik und Naturschutz in Hessen stammen von: Dirk Bönsel, Martin de Jong, Wolfgang Ehmke, Peter Emrich, Benjamin Feller, Brunhilde Göbel, Thomas Gregor, Arthur Händler, Sylvain Hodvina, Gerwin Kasperek, Egbert Korte, Ute Lange, Stefan Meyer, Hasko Friedrich Nesemann, Uwe Raabe, Bernd Sauerwein, Marco Schmidt, Christof Nikolaus Schröder, Antje Schwab, Rainer Stoodt und Michael Uebeler.
Introduction: Hip fracture surgery is associated with high in-hospital and 30-day mortality rates and serious adverse patient outcomes. Evidence from randomised controlled trials regarding effectiveness of spinal versus general anaesthesia on patient-centred outcomes after hip fracture surgery is sparse.
Methods and analysis: The iHOPE study is a pragmatic national, multicentre, randomised controlled, open-label clinical trial with a two-arm parallel group design. In total, 1032 patients with hip fracture (>65 years) will be randomised in an intended 1:1 allocation ratio to receive spinal anaesthesia (n=516) or general anaesthesia (n=516). Outcome assessment will occur in a blinded manner after hospital discharge and inhospital. The primary endpoint will be assessed by telephone interview and comprises the time to the first occurring event of the binary composite outcome of all-cause mortality or new-onset serious cardiac and pulmonary complications within 30 postoperative days. In-hospital secondary endpoints, assessed via in-person interviews and medical record review, include mortality, perioperative adverse events, delirium, satisfaction, walking independently, length of hospital stay and discharge destination. Telephone interviews will be performed for long-term endpoints (all-cause mortality, independence in walking, chronic pain, ability to return home cognitive function and overall health and disability) at postoperative day 30±3, 180±45 and 365±60.
Ethics and dissemination: iHOPE has been approved by the leading Ethics Committee of the Medical Faculty of the RWTH Aachen University on 14 March 2018 (EK 022/18). Approval from all other involved local Ethical Committees was subsequently requested and obtained. Study started in April 2018 with a total recruitment period of 24 months. iHOPE will be disseminated via presentations at national and international scientific meetings or conferences and publication in peer-reviewed international scientific journals.
Trial registration number: DRKS00013644; Pre-results
Background: Liver fibrosis in human immunodeficiency virus (HIV)-infected individuals is mostly attributable to co-infection with hepatitis B or C. The impact of other risk factors, including prolonged exposure to combined antiretroviral therapy (cART) is poorly understood. Our aim was to determine the prevalence of liver fibrosis and associated risk factors in HIV-infected individuals based on non-invasive fibrosis assessment using transient elastography (TE) and serum biomarkers (Fibrotest [FT]).
Methods: In 202 consecutive HIV-infected individuals (159 men; mean age 47 ± 9 years; 35 with hepatitis-C-virus [HCV] co-infection), TE and FT were performed. Repeat TE examinations were conducted 1 and 2 years after study inclusion.
Results: Significant liver fibrosis was present in 16% and 29% of patients, respectively, when assessed by TE (≥ 7.1 kPa) and FT (> 0.48). A combination of TE and FT predicted significant fibrosis in 8% of all patients (31% in HIV/HCV co-infected and 3% in HIV mono-infected individuals). Chronic ALT, AST and γ-GT elevation was present in 29%, 20% and 51% of all cART-exposed patients and in 19%, 8% and 45.5% of HIV mono-infected individuals. Overall, factors independently associated with significant fibrosis as assessed by TE (OR, 95% CI) were co-infection with HCV (7.29, 1.95-27.34), chronic AST (6.58, 1.30-33.25) and γ-GT (5.17, 1.56-17.08) elevation and time on dideoxynucleoside therapy (1.01, 1.00-1.02). In 68 HIV mono-infected individuals who had repeat TE examinations, TE values did not differ significantly during a median follow-up time of 24 months (median intra-patient changes at last TE examination relative to baseline: -0.2 kPa, p = 0.20).
Conclusions: Chronic elevation of liver enzymes was observed in up to 45.5% of HIV mono-infected patients on cART. However, only a small subset had significant fibrosis as predicted by TE and FT. There was no evidence for fibrosis progression during follow-up TE examinations.
The HITRAP linear decelerator currently being set up at GSI will provide slow, few keV/u highly charged ions for atomic physics experiments. The expected beam intensity is up to 105 ions per shot. To optimize phase and amplitude of the RF systems intensity, bunch length and kinetic energy of the particles need to be monitored. The bunch length that we need to fit is about 2 ns, which is typically measured by capacitive pickups. However, they do not work for the low beam intensities that we face. We investigated the bunch length with a fast CVD diamond detector working in single particle counting mode. Averaging over 8 shots yields a clear, regular picture of the bunched beam. Energy measurements by capacitive pickups are limited by the presence of intense primary and partially decelerated beam and hence make tuning of the IH-structure impossible. The energy of the decelerated fraction of the beam behind the first deceleration cavity was determined to about 10 % accuracy with a permanent dipole magnet combined with a MCP. Better detector calibration should help reaching the required 1%. Design of the detectors as well as the results of the measurements will be presented.
Background: Perioperative anaemia leads to impaired oxygen supply with a risk of vital organ ischaemia. In healthy and fit individuals, anaemia can be compensated by several mechanisms. Elderly patients, however, have less compensatory mechanisms because of multiple co-morbidities and age-related decline of functional reserves. The purpose of the study is to evaluate whether elderly surgical patients may benefit from a liberal red blood cell (RBC) transfusion strategy compared to a restrictive transfusion strategy.
Methods: The LIBERAL Trial is a prospective, randomized, multicentre, controlled clinical phase IV trial randomising 2470 elderly (≥ 70 years) patients undergoing intermediate- or high-risk non-cardiac surgery. Registered patients will be randomised only if Haemoglobin (Hb) reaches ≤9 g/dl during surgery or within 3 days after surgery either to the LIBERAL group (transfusion of a single RBC unit when Hb ≤ 9 g/dl with a target range for the post-transfusion Hb level of 9–10.5 g/dl) or the RESTRICTIVE group (transfusion of a single RBC unit when Hb ≤ 7.5 g/dl with a target range for the post-transfusion Hb level of 7.5–9 g/dl). The intervention per patient will be followed until hospital discharge or up to 30 days after surgery, whichever occurs first. The primary efficacy outcome is defined as a composite of all-cause mortality, acute myocardial infarction, acute ischaemic stroke, acute kidney injury (stage III), acute mesenteric ischaemia and acute peripheral vascular ischaemia within 90 days after surgery. Infections requiring iv antibiotics with re-hospitalisation are assessed as important secondary endpoint. The primary endpoint will be analysed by logistic regression adjusting for age, cancer surgery (y/n), type of surgery (intermediate- or high-risk), and incorporating centres as random effect.
Discussion: The LIBERAL-Trial will evaluate whether a liberal transfusion strategy reduces the occurrence of major adverse events after non-cardiac surgery in the geriatric population compared to a restrictive strategy within 90 days after surgery.
Trial registration: ClinicalTrials.gov (identifier: NCT03369210).
Due to massive energetic investments in woody support structures, trees are subject to unique physiological, mechanical, and ecological pressures not experienced by herbaceous plants. Despite a wealth of studies exploring trait relationships across the entire plant kingdom, the dominant traits underpinning these unique aspects of tree form and function remain unclear. Here, by considering 18 functional traits, encompassing leaf, seed, bark, wood, crown, and root characteristics, we quantify the multidimensional relationships in tree trait expression. We find that nearly half of trait variation is captured by two axes: one reflecting leaf economics, the other reflecting tree size and competition for light. Yet these orthogonal axes reveal strong environmental convergence, exhibiting correlated responses to temperature, moisture, and elevation. By subsequently exploring multidimensional trait relationships, we show that the full dimensionality of trait space is captured by eight distinct clusters, each reflecting a unique aspect of tree form and function. Collectively, this work identifies a core set of traits needed to quantify global patterns in functional biodiversity, and it contributes to our fundamental understanding of the functioning of forests worldwide.
(1) Background: Refractory acute graft-versus-host disease (R-aGvHD) remains a leading cause of death after allogeneic stem cell transplantation. Survival rates of 15% after four years are currently achieved; deaths are only in part due to aGvHD itself, but mostly due to adverse effects of R-aGvHD treatment with immunosuppressive agents as these predispose patients to opportunistic infections and loss of graft-versus-leukemia surveillance resulting in relapse. Mesenchymal stromal cells (MSC) from different tissues and those generated by various protocols have been proposed as a remedy for R-aGvHD but the enthusiasm raised by initial reports has not been ubiquitously reproduced.
(2) Methods: We previously reported on a unique MSC product, which was generated from pooled bone marrow mononuclear cells of multiple third-party donors. The products showed dose-to-dose equipotency and greater immunosuppressive capacity than individually expanded MSCs from the same donors. This product, MSC-FFM, has entered clinical routine in Germany where it is licensed with a national hospital exemption authorization. We previously reported satisfying initial clinical outcomes, which we are now updating. The data were collected in our post-approval pharmacovigilance program, i.e., this is not a clinical study and the data is high-level and non-monitored.
(3) Results: Follow-up for 92 recipients of MSC-FFM was reported, 88 with GvHD ≥°III, one-third only steroid-refractory and two-thirds therapy resistant (refractory to steroids plus ≥2 additional lines of treatment). A median of three doses of MSC-FFM was administered without apparent toxicity. Overall response rates were 82% and 81% at the first and last evaluation, respectively. At six months, the estimated overall survival was 64%, while the cumulative incidence of death from underlying disease was 3%.
(4) Conclusions: MSC-FFM promises to be a safe and efficient treatment for severe R-aGvHD.
Background: The human chromosomal region 9p21.3 has been shown to be strongly associated with Coronary Heart Disease (CHD) in several Genome-wide Association Studies (GWAS). Recently, this region has also been shown to be associated with Aggressive Periodontitis (AgP), strengthening the hypothesis that the established epidemiological association between periodontitis and CHD is caused by a shared genetic background, in addition to common environmental and behavioural risk factors. However, the size of the analyzed cohorts in this primary analysis was small compared to other association studies on complex diseases. Using our own AgP cohort, we attempted to confirm the described associations for the chromosomal region 9p21.3. Methods: We analyzed our cohort consisting of patients suffering from the most severe form of AgP, generalized AgP (gAgP) (n = 130) and appropriate periodontally healthy control individuals (n = 339) by genotyping four tagging SNPs (rs2891168, rs1333042, rs1333048 and rs496892), located in the chromosomal region 9p21.3, that have been associated with AgP. Results: The results confirmed significant associations between three of the four SNPs and gAgP. The combination of our results with those from the study which described this association for the first time in a meta-analysis of the four tagging SNPs produced clearly lower p-values compared with the results of each individual study. According to these results, the most plausible genetic model for the association of all four tested SNPs with gAgP seems to be the multiplicative one. Conclusion: We positively replicated the finding of an association between the chromosomal region 9p21.3 and gAgP. This result strengthens support for the hypothesis that shared susceptibility genes within this chromosomal locus might be involved in the pathogenesis of both CHD and gAgP.
Introduction: Evidence from a number of open-label, uncontrolled studies has suggested that rituximab may benefit patients with autoimmune diseases who are refractory to standard-of-care. The objective of this study was to evaluate the safety and clinical outcomes of rituximab in several standard-of-care-refractory autoimmune diseases (within rheumatology, nephrology, dermatology and neurology) other than rheumatoid arthritis or non-Hodgkin's lymphoma in a real-life clinical setting.
Methods: Patients who received rituximab having shown an inadequate response to standard-of-care had their safety and clinical outcomes data retrospectively analysed as part of the German Registry of Autoimmune Diseases. The main outcome measures were safety and clinical response, as judged at the discretion of the investigators.
Results: A total of 370 patients (299 patient-years) with various autoimmune diseases (23.0% with systemic lupus erythematosus, 15.7% antineutrophil cytoplasmic antibody-associated granulomatous vasculitides, 15.1% multiple sclerosis and 10.0% pemphigus) from 42 centres received a mean dose of 2,440 mg of rituximab over a median (range) of 194 (180 to 1,407) days. The overall rate of serious infections was 5.3 per 100 patient-years during rituximab therapy. Opportunistic infections were infrequent across the whole study population, and mostly occurred in patients with systemic lupus erythematosus. There were 11 deaths (3.0% of patients) after rituximab treatment (mean 11.6 months after first infusion, range 0.8 to 31.3 months), with most of the deaths caused by infections. Overall (n = 293), 13.3% of patients showed no response, 45.1% showed a partial response and 41.6% showed a complete response. Responses were also reflected by reduced use of glucocorticoids and various immunosuppressives during rituximab therapy and follow-up compared with before rituximab. Rituximab generally had a positive effect on patient well-being (physician's visual analogue scale; mean improvement from baseline of 12.1 mm).
Conclusions: Data from this registry indicate that rituximab is a commonly employed, well-tolerated therapy with potential beneficial effects in standard of care-refractory autoimmune diseases, and support the results from other open-label, uncontrolled studies.
Background: Persistent antiphospholipid antibodies (aPL) constitute the serological hallmark of the antiphospholipid syndrome (APS). Recently, various new assay technologies for the detection of aPL better suited to multiplex reaction environments than ELISAs emerged. We evaluated the diagnostic performance of such a novel line immunoassay (LIA) for the simultaneous detection of 10 different aPL.
Methods: Fifty-three APS patients and 34 healthy controls were investigated for criteria (antibodies against cardiolipin [aCL], β2-glycoprotein I [aβ2-GPI]) and non-criteria aPL (antibodies against phosphatidic acid [aPA], phosphatidyl-choline [aPC], -ethanolamine [aPE], -glycerol [aPG], -inositol [aPI], -serine [aPS], annexin V [aAnnV], prothrombin [aPT]) IgG and IgM by LIA. Criteria aPL were additionally determined with the established Alegria (ALE), AcuStar (ACU), UniCap (UNI), and AESKULISA (AES) systems and non-criteria aPL with the AES system. Diagnostic performance was evaluated with a gold standard for criteria aPL derived from the results of the four established assays via latent class analysis and with the clinical diagnosis as gold standard for non-criteria aPL.
Results: Assay performance of the LIA for criteria aPL was comparable to that of ALE, ACU, UNI, and AES. For non-criteria aPL, sensitivities of the LIA for aPA-, aPI-, aPS-IgG and aPA-IgM were significantly higher and for aPC-, aPE-, aAnnV-IgG and aPC- and aPE-IgM significantly lower than AES. Specificities did not differ significantly.
Conclusions: The LIA constitutes a valuable diagnostic tool for aPL profiling. It offers increased sensitivity for the detection of aPL against anionic phospholipids. In contrast, ELISAs exhibit strengths for the sensitive detection of aPL against neutral phospholipids.